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ABSTRACT   In 2003, the American Cancer Society updated its guidelines for early detection
of breast cancer based on recommendations from a formal review of evidence and a recent
workshop. The new screening recommendations address screening mammography, physical
examination, screening older women and women with comorbid conditions, screening
women at high risk, and new screening technologies. (CA Cancer J Clin 2003;54:141-169.)
© American Cancer Society, 2003.
INTRODUCTION
The underlying premise for breast cancer screening is that it allows for the
detection of breast cancers before they become palpable. Breast cancer is a
progressive disease, and small tumors are more likely to be early stage disease, have a
better prognosis, and are more successfully treated.1 In this document, we use the
term screening to refer to the testing of asymptomatic individuals for the detection of
occult disease. Early detection means the application of a technique or strategy that
results in earlier diagnosis of nonpalpable, as well as palpable, breast cancers than
otherwise would have occurred.
The efficacy of breast cancer screening has been demonstrated in randomized
controlled trials (RCTs) and observational studies; thus,most organizations that issue
recommendations endorse regular mammography as an important part of preventive
care. However, while it is true that screen-detected breast cancers are associated with
reduced morbidity and mortality, the majority of women who participate in
screening will not develop breast cancer in their lifetime. Screening also will not
benefit all women who are diagnosed with breast cancer, and it leads to harms in
women who undergo biopsy for abnormalities that are not breast cancer, as well as
those who are overtreated for ductal carcinoma in situ (DCIS) that might have been
nonprogressive. Thus, in addition to benefits, limitations of screening and harms
associated with screening are addressed in this guideline update.
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In 1997, the American Cancer Society
(ACS) updated its guidelines for breast cancer
screening.2 The most notable change in the
1997 guideline update was the recom-
mendation that women should begin annual
screening at age 40; the previous guideline had
recommended mammography every one to
two years for women beginning at age 40, and
annual mammography for women beginning at
age 50.3 The 1997 update also noted that there
was no chronological age at which screening
should stop, emphasizing that as long as a
woman was in good health she likely 
would benefit from breast cancer screening.
Recommendations for clinical breast exam-
ination (CBE) were modified by adding the
advice that women 40 and older schedule
annual CBE close to the time of, and before,
their annual mammograms.2
Guideline Development 
In 2002, the ACS convened an expert panel
to review the existing early detection guidelines
based on evidence that has accumulated since
the last revision. The panel was divided into
work groups to review recent evidence and
develop recommendations regarding: (1)
mammography; (2) physical examination; (3)
screening of older women and women with
comorbid conditions; (4) screening high-risk
women; and (5) screening with new tech-
nologies.
During the current guideline review,
literature related to breast cancer screening
published between January 1997 and
September 2002, including new screening tests,
was identified using MEDLINE (National
Library of Medicine), bibliographies of
identified articles, personal files of panel
members, and unpublished manuscripts. Expert
panel members reviewed articles using specified
criteria and discussed them during a series of
conference calls. Each work group developed
recommendations, rationale, and evidence
summaries, and reviewed the summaries
developed by the other work groups prior to a
September 2002 workshop. When evidence 
was insufficient or lacking, the final
recommendations incorporated the expert
opinions of the panel members. During the
conference calls and workshop, consensus was
reached on the key issues within the guideline
recommendations. Following the workshop,
ACS Breast Cancer Advisory Group members
deliberated over the guideline modifications.
Each work group member and workshop
attendee was given the opportunity to review
the draft of this manuscript. Numerous
professional, advocacy, and governmental
organizations also were invited to review the
draft guidelines.
RECOMMENDATIONS, RATIONALE, AND EVIDENCE
Summary of Guidelines
A summary of the update of the ACS
guidelines for early breast cancer detection is
shown in Table 1.
SCREENING WITH MAMMOGRAPHY
Recommendation 
Women at average risk should begin annual
mammography at age 40.Women should have
an opportunity to become informed about 
the benefits, limitations, and potential harms
associated with regular screening.
Rationale and Evidence 
Since 1997, there have been updates in 
the evidence from RCTs of breast cancer
screenings. Several other reports have
challenged the value of screening for breast
cancer with mammography,4-7 leading to a surge
of new literature reexamining the underlying
evidence related to breast cancer screening.The
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updated clinical trial results from individual
studies and meta-analyses continue to show a
significant mortality reduction from mammo-
graphy screening, and this finding is further
supported by evidence from organized
screening programs.
Evidence From Randomized Trials of Breast
Cancer Screening
The primary evidence supporting the
recommendation for periodic screening for
breast cancer with mammography derives from
seven RCTs. Two of the trials took place in
North America, one in Scotland, and four in
Sweden. One additional trial is underway in the
United Kingdom evaluating the benefit of
beginning screening in a woman’s early 40s.8 At
the time of the previous guideline update in
1997, individual trials and meta-analyses of all
trials combined showed statistically significant
mortality reductions for women aged 40 to 69
associated with an invitation to screening.9-14
Since the last guideline review, updated results
from several of the RCTs have been
published.15-20
Long-term follow-up data from the UK Trial
of Early Detection of Breast Cancer (TEDBC)
and from the Edinburgh trial of breast cancer
screening were published in the Lancet in
1999.15,16 The TEDBC is a nonrandomized study
comparing observed versus expected breast
cancer mortality in women aged 45 to 64 in
eight centers, consisting of two mammography
centers, two breast self-examination (BSE)
centers, and four comparison centers. After
adjusting for pre-trial mortality rates, breast
cancer mortality was 27% lower in women aged
45 to 69 in the two centers in which women
underwent mammography compared with the
comparison centers. A 35% breast cancer
mortality reduction was observed in cohorts
aged 45 to 46 at entry into the study. Since the
effect began to emerge after three to four years,
it cannot be attributed to diagnosis after age 50
among women enrolled into the study in their
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Women at Average Risk Begin mammography at age 40.
For women in their 20s and 30s, it is recommended that clinical breast examination be part of a
periodic health examination, preferably at least every three years. Asymptomatic women aged 40
and over should continue to receive a clinical breast examination as part of a periodic health
examination, preferably annually.
Beginning in their 20s, women should be told about the benefits and limitations of breast self-
examination (BSE). The importance of prompt reporting of any new breast symptoms to a health
professional should be emphasized. Women who choose to do BSE should receive instruction
and have their technique reviewed on the occasion of a periodic health examination. It is
acceptable for women to choose not to do BSE or to do BSE irregularly.
Women should have an opportunity to become informed about the benefits, limitations, and
potential harms associated with regular screening.
Older Women Screening decisions in older women should be individualized by considering the potential
benefits and risks of mammography in the context of current health status and estimated life
expectancy. As long as a woman is in reasonably good health and would be a candidate for
treatment, she should continue to be screened with mammography.
Women at Increased Risk Women at increased risk of breast cancer might benefit from additional screening strategies
beyond those offered to women of average risk, such as earlier initiation of screening, shorter
screening intervals, or the addition of screening modalities other than mammography and
physical examination, such as ultrasound or magnetic resonance imaging. However, the evidence
currently available is insufficient to justify recommendations for any of these screening
approaches.
TABLE 1
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40s.15 In the Edinburgh trial
follow-up, the investigators
applied an improved method
of adjusting for socio-
economic status and censored
breast cancer diagnoses more
than three years after the
conclusion of the study, since
cases diagnosed after three
years were unlikely to have
been prior false negatives;
29% fewer breast cancer
deaths were observed in the
group invited to screening
compared with an initial
estimate of 13 percent.16 The
investigators also reported
that there was no significant
difference in the observed
benefit based on age at
randomization.
Updated results from the
Canadian National Breast
Cancer Screening Trial
(NBSS-1 and NBSS-2) have
been reported since 1997.17,18
In 2000, Miller, et al. reported
13-year follow-up results
from the NBSS-2, which
compared annual two-view
mammography and CBE
with annual CBE only in
women aged 50 to 59 at
randomization. The authors
reported no difference in the
breast cancer mortality rate in
the group randomized to
receive an invitation to annual
mammography and CBE
compared with the group
invited to receive CBE only
(RR = 1.02), and concluded
that mammography provided
no additional advantage
compared with carefully
conducted CBE.17 In 2002,
the Canadian investigators reported updated
results from the NBSS-1, which compared
annual mammography and CBE with usual care
in women aged 40 to 49.18 After 11 to 16 years
of follow-up there was no difference in the
breast cancer mortality rate in the group invited
to mammography screening compared with
CBE with usual care (RR = 0.97).
In 2000, Tabár and colleagues reported 20-
year follow-up of the Swedish Two-County
Trial of breast cancer screening.19 With follow-
up through 1998, there was a statistically
significant 32% reduction in mortality in
women aged 40 to 69 (RR = 0.68, 95%
confidence interval (CI) 0.59 to 0.80) associated
with an invitation to screening. A larger,
consistent effect was observed in each of the two
counties for women aged 50 to 69. Results for
women aged 40 to 49 differed between the two
counties, with a substantial reduction in breast
cancer mortality in the W-county (RR = 0.76,
95% CI 0.42 to 1.40), but not in the E-county
(RR = 1.06, 95% CI 0.65 to 1.76).Tabár, et al.
have reported previously that this inconsistency
is explained by the observed higher fatality rates
in nonattenders to screening in the invited
group in the E-county.21
Swedish investigators recently updated the
overview analysis of the Swedish trials of
mammography screening based on follow-up
to 1996.20 With a median follow-up time from
randomization to the end of follow-up of 15.8
years, the investigators observed an overall 21%
statistically significant reduction in breast cancer
mortality among women aged 40 to 74 at
randomization associated with an invitation to
mammography (RR = 0.79).
As part of the evidence review of the US
Preventive Services Task Force (USPSTF), a
new meta-analysis of the RCTs was conduct-
ed by Humphrey, et al.22 and published
simultaneously with the updated USPSTF
guidelines.23 The meta-analysis of trial results
(excluding the Edinburgh trial) from all age
groups showed a statistically significant 16%
mortality reduction associated with an
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invitation to screening (RR = 0.84). Similar
meta-analyses were conducted for women aged
40 to 49 at randomization, with results leading
the authors to conclude that the risk reduction
from mammography screening does not differ
substantially by age, although absolute benefits
are lower in women under age 50 compared
with women aged 50 and over.The authors of
the updated reports from Edinburgh and the
TEDBC reached similar conclusions about
age-specific benefits.15,16
The most recent results from the
randomized clinical trials are shown in Table 2.24
While there is variation in the observed
mortality reductions, a meta-analysis of the
most recent results showed a 24% mortality
reduction associated with an invitation to
screening. Further, although the trials vary
somewhat in their design, their results are
uniformly consistent with respect to the
relationships between the observed shift in stage
at diagnosis and reduction in mortality, i.e.,
those trials that achieved the greatest reduction
in the relative risk of being diagnosed with a
node-positive breast cancer also have shown the
greatest mortality reductions.25,26
In October 2001, the Lancet published a
research letter by Ole Olsen
and Peter Gøtzsche7 from the
Nordic Cochrane Centre in
Copenhagen. The authors
evaluated the randomized
trials of breast cancer
screening through meta-
analysis, concluding that five
of the seven trials were
flawed and should not be
regarded as providing reliable
scientific evidence.Olsen and
Gøtzsche further suggested
that breast cancer mortality
was an unreliable endpoint,
and that only comparison of
all-cause mortality between
the experimental and control
groups could serve as an
unbiased endpoint. Based on
their meta-analysis, which
was restricted to the Malmö
and Canadian trials, the
authors found no evidence of
a reduced mortality asso-
ciated with an invitation to
mammography (RR = 1.0),
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Most Recently Published Results of the Breast Cancer Screening Trials on Breast Cancer
Mortality Reduction With Invitation to Screening  
Study Age Range Percentage Mortality Reduction (95% CI†)
HIP 40 - 64 24 (7, 38)
Malmö 45 - 69 19 (-8, 39)
Two-County Trial, Sweden 40 - 74 32 (20, 41)
Edinburgh 45 - 64 21 (-2, 40)
Stockholm 40 - 64 26 (-10, 50)
Canada NBSS-1 40 - 49 -3 (-26, 27)
Canada NBSS-2 50 - 59 -2 (-33, 22)
Gothenburg 39 - 59* 16 (-39, 49)
All Trials Combined 39 - 74 24 (18, 30)
TABLE 2
*There are more recent publications from the Gothenburg trial but they refer only to the under-50 
age group.
†CI = Confidence interval.
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and concluded that there was
no reliable evidence that
screening reduced breast
cancer mortality. Several
guideline groups, national
boards of health, and nu-
merous individual authors
have provided formal cri-
tiques of the methodology
and conclusions of Olsen and
Gøtzsche.20,22,24,26-30 The re-
views uniformly concluded
that the evidence provided
by the Cochrane Review did
not support the claim 
that methodological short-
comings in the conduct of
the trials were of such
significance to invalidate the
conclusion that screening for
breast cancer with mam-
mography reduces breast
cancer mortality.
Evidence From Service
Screening
The inherent limitations of
the breast cancer screening
RCTs to estimate the benefits
associated with exposure to
modern mammography have
led to increased interest in
evaluating the impact of screening in the
community setting, also referred to as service
screening. Service screening evaluation can
estimate breast cancer mortality for women who
actually attend community screening programs
and for the population as a whole. Service
screening evaluation can also be used to attribute
differences in mortality over time to screening,
improvements in therapy, and increased
awareness.31 However, establishing the relative
value between screening and nonscreening
factors is complex and can be only indirectly
estimated.
Blanks, et al. reported on the impact of the
UK National Health Service breast cancer
screening program in women aged 55 to 69
years between 1990 and 1998,32 estimating a
21.3% reduction in breast cancer mortality,
with a smaller direct effect of mammography
(6.4%) compared with increased awareness and
improvements in therapy (14.9%). Jonsson and
colleagues have reported on service screening
in Sweden for women aged 40 to 49,33 and 50
to 69,34 and the investigators concluded that the
estimated mortality reductions were consistent
with the estimates from the RCTs.
Two additional investigations from Sweden
were able to classify breast cancer cases before
and after the introduction to screening on the
basis of exposure to screening.31,35 In the most
recent report,35 which expanded an earlier
analysis to seven counties in the Uppsala
region, Duffy and colleagues compared breast
cancer mortality in the prescreening and
postscreening periods among women aged 40
to 69 in six counties and 50 to 69 in a seventh
county. Overall, they observed a 44% mortality
reduction in women who underwent screening
and a 39% reduction in overall breast cancer
mortality after adjustment for selection bias
associated with the policy of offering screening
to the population.35 Because the authors were
able to distinguish between screened and
unscreened cohorts, they estimated that about
two-thirds of the observed mortality reductions
were attributable to screening, with the
remainder due to improvements in therapy and
increased awareness. While Blanks, et al.
estimate a smaller benefit of mammography,
they acknowledge they were unable to identify
which among the breast cancer deaths in the
postscreening period were from cases diagnosed
before screening was health policy.31,35 These
data demonstrated that organized screening
with high rates of attendance in a setting that
achieves a high degree of programmatic quality
assurance did achieve breast cancer mortality
reductions equal to or greater than those
observed in the randomized trials.
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Breast cancer mortality reductions associat-
ed with screening have been reported from 
the Florence, Italy Screening program, also
comparing breast cancer mortality among
attenders and nonattenders to screening, and 
in the population before and after the
introduction of screening between 1990 and
1996.36 The incidence-based mortality ratio
(i.e., the rate of fatal incident breast cancer
cases) comparing 1990 to 1996 with 1985 to
1986 shows a 50% reduction in the rate of
breast cancer deaths (RR = 0.50, 95% CI 0.38
to 0.66).After excluding the breast cancer cases
diagnosed at the first screening examination
(i.e., the prevalent screening round), the rate of
Stage II or higher breast cancer cases was 42%
lower in screened women compared with the
women diagnosed with breast cancer that had
not been invited to screening (RR = 0.58, 95%
CI 0.45 to 0.74). The investigators concluded
that breast cancer mortality reductions were
attributable to improvements in therapy and the
introduction of a breast cancer screening
program.
These data demonstrate that modern,
organized screening programs with high rates
of attendance can achieve breast cancer
mortality reductions equal to or greater than
those observed in the RCTs. Insofar as
additional RCTs of breast cancer screening are
unlikely, the evaluation of service screening
represents an important new development for
several reasons, specifically by measuring the
value of modern mammography in the
community and measuring the benefit from
mammography screening to women who
actually get screened.
Screening Intervals
Mortality reductions for women aged 40 to
69 have been observed in trials that screened at
intervals of 12 and 24 (and over) months, and
thus, some guidelines recommend screening at
an interval of one-two years. However, data
from two trials13,14 and inferential evidence used
to estimate the duration of
the detectable pre-clinical
phase,1,37 i.e., sojourn time,
have provided persuasive
evidence that younger
women likely will benefit
more from annual screening
compared with screening 
at two-year intervals, a
conclusion also reached in
the recent USPSTF evidence
review.22 Further, data from
both RCTs and from service
screening programs have
shown that the proportional
incidence of interval cancers
in the period after a normal
screening examination is
higher in younger women
compared with older
women, suggesting faster
growth rates in younger
women.14,38,39 Tabár and
colleagues have estimated
that tumor sojourn times
lengthen with increasing age,
and using Two-County trial
data have estimated the mean
sojourn time for women by
age as follows: 40 to 49 = 2.4
years, 50 to 59 = 3.7 years, 60
to 69 = 4.2 years, and 70 to
79 = 4 years.19
Modeling data also have
suggested that progressively shorter screening
intervals result in both the detection of tumors
at smaller sizes and in decreased mortality rates.
Estimating tumor characteristics associated with
screening intervals of 24, 12, and 6 months,
Michaelson, et al. showed that shorter screening
intervals were associated with greater
reductions in the proportion of cases diagnosed
with distant metastases.40 Also, in a subsequent
modeling analysis of 1,352 women from the
Van Nuys Breast Cancer Center between 1966
and 1990,Michaelson, et al. showed that smaller
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tumor size was highly correlated with longer
survival time independent of method of cancer
detection.41
While sojourn times lengthen with
increasing age, these data provide only a limited
basis for establishing screening intervals, and 
in particular, they provide only a rough
approximation for an interval that should not
be exceeded, since the recommended screening
interval should always be shorter than the
estimated mean sojourn time. Since the goal of
screening is the reduction in the incidence rate
of advanced disease, the screening interval
should be set for a period of time in which
adherence to routine screening is likely to result
in the detection of the majority of cancers
while still occult and localized. While annual
screening likely is more beneficial for all
women,1,40,42 the importance of annual
screening clearly is greater in premenopausal
women (< 55) compared with postmenopausal
women. However, given the prognostic value of
smaller tumors, and the finding that annual
screening results in more favorable tumor
characteristics in both pre- and postmenopausal
women, annual screening may offer advantages
over biennial screening well into the
postmenopausal period.43
Limitations of Mammography and Harms
Associated With Screening 
As is the case with any screening exam-
ination, the goal of breast cancer screening is to
detect occult breast cancer in a population of
women in which the great majority will not
have breast cancer on the occasion of a regular
examination, and the large majority will not
develop breast cancer in their lifetime.Although
the efficacy of mammography has been
demonstrated, it does not achieve perfect
sensitivity or specificity in women undergoing
screening, and as such, the issue of adverse
consequences for women who do and who do
not have breast cancer has been a source of
growing attention, and has become one of the
core issues in recent debates about
mammography. False negatives can be
attributed to inherent technological limitations
of mammography, quality assurance failures, and
human error; false positives also can be
attributed to these factors as well as to
heightened medical-legal concerns over the
consequence of missed cancers. Further, in
some instances, a patient’s desire for definitive
findings in the presence of a low-suspicion
lesion also contributes to false positives. The
consequences of these errors include missed
cancers, with potentially worse prognosis, as
well as anxiety and harms associated with
interventions for benign or nonobligate
precursor lesions.
This issue of limitations and harms is both
important and complex, since mammography’s
shortcomings are due to the interplay between
host characteristics (age, risk, breast density, and
tumor growth rates) and provider factors
(technical limitations and quality assurance
failures). Thus, theoretically, there is at least
some level of limitations and harms that is
inherent to breast cancer screening and
unavoidable. Beyond this level are potential
improvements in screening and reductions in
harms that could be achieved through various
technical and system-related interventions.This
relationship between risk, benefit, limitations,
and harms is complicated by the fact that not
only is it multifactorial, but also that individual
women likely will weigh the benefits,
limitations, and harms of screening differently
depending on their age, values, and their
understanding of the issues. Still, there is
concern that the rate of false-positive
mammography and benign biopsy is excessive
and could be reduced with improvements in
screening quality, although other factors such as
medical-legal pressures and individual anxiety
about uncertainty may partly be outside the
influence of additional improvements in
quality.44 There also is agreement that steps
should be taken to reduce anxiety associated
with screening,45 i.e., the waiting time to
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diagnosis,46,47 and that there should be
conscientious efforts applied toward informing
women about the likelihood of both false-
negative and false-positive findings.48
A number of investigations have attempted to
measure the extent of psychological and physi-
cal harms associated with false-positive
mammography and, in particular,have attempted
to identify whether or not harms are lasting and
have consequences for psychological well-being
and subsequent screening. In general, the
evidence suggests that some women experience
anxiety related to screening, and a greater
percentage experience anxiety related to false-
positive results, but for most women
psychological distress is short-lived and does not
have lasting consequences on either stress levels
or likelihood of subsequent screening.47,49 A
recent study by Schwartz and colleagues revealed
that women are aware that false-positive results
occur, accept false-positive results as a part of
screening, and do not regard false positives as an
important harm in the context of the underlying
goal of early breast cancer detection.48 However,
women’s awareness of the chance of a false-
positive finding and acceptance of false positives
as a cost of screening should not detract from
organized efforts to provide information about
the range of screening outcomes, to achieve an
acceptable rate of false-positive results in
screening programs, and to mitigate the
spectrum of harms. Further, health professionals
must become more sensitive to both short-term
and long-term effects of false-positive results.
As use of mammography has increased,
concerns have been raised about detection and
overtreatment of DCIS.50,51 Although the
detection of DCIS is an inevitable consequence
of mammographic screening, the concern that
not all DCIS is progressive has to be weighed
against the estimate that a substantial portion is
progressive.The actual fraction is not known,and
historical estimates from case series may not be
directly generalizable to cases identified through
mammographic screening.52 However, in one
series, invasive breast cancer developed in over
half of women with low-grade DCIS lesions
identified on biopsy but not treated.53 Further,
incomplete excision of DCIS or failure to excise
DCIS associated with an invasive cancer is a
determinant for local failure.54,55 As with invasive
breast cancer, the histologic subtype and grade of
DCIS can be regarded as having prognostic value
in relation to risk of recurrence of invasive
cancer or DCIS.Thus, there is little question that
some women benefit from detection and
treatment of DCIS. However, since some DCIS
is not progressive, diagnostic evaluation and
treatment of DCIS lesions that would not
progress to invasive disease is a harm associated
with screening, although the extent of harm is
uncertain, as is how it might be avoided.
Overtreatment of a progressive DCIS lesion that
could be cured with less aggressive treatment also
represents a harm, although it should not be
attributed to screening.
At this time, the majority of detected DCIS
occurs as a result of identification of small
lesions on a mammogram that are perceived to
be important. It is not possible through image
evaluation to either distinguish DCIS from
invasive breast cancer or progressive DCIS from
nonprogressive DCIS. Schwartz and colleagues
have recommended that information provided
to women undergoing mammography should
include a discussion about detection of DCIS.48
Important questions remain about how to
identify those noninvasive ductal cancers that
are most likely to progress to become invasive
cancers.
PHYSICAL EXAMINATION
Recommendations  
Clinical Breast Examination
For average-risk asymptomatic women in
their 20s and 30s, it is recommended that CBE
be part of a periodic health examination,
preferably at least every three years.The exam
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should include BSE instruction for the purpose
of gaining familiarity with breast composition.
Information should be provided about the
benefits and limitations of CBE and BSE, and it
should be emphasized that breast cancer risk is
very low for women in their 20s and gradually
increases with age. The importance of prompt
reporting of any new symptoms to a health
professional also should be emphasized.
Asymptomatic women aged 40 and over
should continue to receive CBE as part of a
periodic health examination, preferably
annually. Beginning at age 40, discussion during
CBE should include information about
screening mammography. There may be some
benefit to performing the CBE shortly before
the mammogram. At the time of CBE, the
benefits and limitations of physical examination
and mammography should be discussed with
the patient.
Breast Self-Examination  
Beginning in their 20s, women should be
told about the benefits and limitations of BSE.
The importance of prompt reporting of any
new breast symptoms to a health professional
should be emphasized.Women who choose to
do BSE should receive instruction and have
their technique reviewed on the occasion of a
periodic health examination. It is acceptable for
women to choose not to do BSE or to do BSE
irregularly.
Rationale and Evidence
The logic for the earlier detection of clinical
findings in the breast is analogous to the logic
for detecting breast cancer before a tumor is
palpable.With increasing tumor size, even after
breast cancers become palpable, the likelihood
of regional and distant metastasis increases.
Long-term survival measured either with
registry data or with data from RCTs is poorer
with each incremental 5 mm increase in tumor
size.19,56 For average-risk women under age 40,
earlier detection of palpable tumors with CBE
or BSE can lead to earlier therapy. After age 
40, CBE and BSE are regarded as adjunctive
because mammography does not achieve
perfect sensitivity. Although there are no direct
clinical data linking an increased rate of breast
preservation to CBE or BSE, it is plausible that
earlier detection of symptomatic breast cancer
results in a greater probability for a breast
conserving approach.
The evidence supporting the value of CBE
and BSE as methods of reducing breast cancer
mortality is limited and mostly inferential,
although there is no definitive prospective
RCT evidence from which to draw
conclusions about either exam. Thus, current
recommendations rely on existing evidence, but
also on expert opinion based on a recognition
that population-based studies continue to show
a relatively large proportion of self-detected
cancers.
Clinical Breast Examination
Today, mammography and clinical breast
examination are recommended to women 40
and older because: (1) there are RCT data
showing the combination of mammography
and CBE was associated with lower breast
cancer mortality,16,57 and (2) evidence from
these RCTs and demonstration projects
showed that some cancers detected by CBE
were not detected by mammography.16,57,58
The USPSTF recommends mammography
with or without CBE, and it has concluded that
there is insufficient evidence to recommend for
or against breast cancer screening with CBE
alone.23 Evaluation of CBE as a detection
modality has generally focused on the
performance characteristics of the test, i.e.,
sensitivity, specificity, and positive predictive
value.57-60 On all aspects, performance
characteristics are poorer than those of
mammography. Sensitivity of CBE in particular
was estimated in a recent meta-analysis to be
only 54 percent.61 While noting that two trials
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demonstrated breast cancer mortality
reductions associated with the combination of
mammography and CBE,16,62 the USPSTF
concluded there was insufficient evidence to
quantify the incremental benefits of adding
CBE to mammography.23 This particular
question is more pertinent today, since much of
the RCT data related to the value of CBE
combined with mammography derives from a
period that predates modern breast imaging.
The proportion of breast cancers not visible
with modern, high-quality mammography
appears to be considerably lower today than in
the past.60,63,64
Based on findings from 752,081 CBEs,Bobo
and colleagues reported that 6.9 percent of 
all CBEs were coded as abnormal, and that 
five cancers were detected per 1,000
examinations.60 However, only 5.1 percent of
the malignancies (193/3,753), or 2.56 per
10,000 CBE exams, were detected in women
with an abnormal CBE and benign findings on
the mammogram. Since women with self-
detected breast symptoms were 7.2 times as
likely to have an abnormal exam, it is likely that
some proportion of these CBE-positive cases
were first detected by women themselves,
leading to an even lower rate of breast cancer
detection attributable to CBE alone.
Newcomer, et al. recently reported on the
mode of detection in 2,341 Wisconsin women
greater than or equal to the age of 50 diagnosed
with breast cancer from 1988 to 1991.Women
were asked how their breast cancer was first
discovered—48 percent were self-detected, 41
percent were detected by mammography,
and 11 percent were detected by CBE.63
Oestreicher, et al. evaluated the sensitivity of
CBE in 468 women diagnosed with breast
cancer within a year of a screening CBE.64
Overall sensitivity was estimated to be 35
percent, but the majority of these cases (83.6
percent) also were detected by mammo-
graphy. Among women with false-negative
mammograms, 37 percent were detected by
CBE, but overall only 5.7 percent (n = 27) of
breast cancers were diagnosed by CBE only.64
Sensitivity ranged from 17.2 percent for tumors
less than or equal to 0.5 cm to 58.3 percent for
tumors greater than or equal to 2.1 cm, and was
lower in younger women and women with
higher body weight.
At this time, it is unclear what CBE
contributes to detection of breast cancer,
although it is likely that in presumably
asymptomatic women the contribution is small.
When done prior to mammography, CBE may
identify an area of suspicion that will not be
visible on mammography and/or provide
information that guides subsequent imaging
exams. As a growing proportion of women are
receiving regular mammograms, the relative
contribution of CBE to early breast cancer
detection and its cost-effectiveness warrant
renewed attention. At this time, in women
screened with mammography, the cancer
detection rate for CBE appears to be low, and
the evidence for breast cancer mortality
reduction associated with CBE is weak and
indirect.
However, apart from some contribution to
breast cancer detection, CBE may serve an
additional, separate function: it can provide the
occasion to raise awareness about breast cancer
and to provide accurate education on the
variety of breast cancer-related topics, including
information about breast symptoms, genetics,
risk factors, and newer cancer detection
technologies. The consensus opinion of the
ACS review panel was that until more
informative scientific evidence is available,
periodic CBE is recommended with the
additional endorsement that the occasion of a
CBE should be used to raise awareness about
the early detection of breast cancer. In
rendering this opinion, there were some panel
members who believed that the evidence
against the benefit of CBE was not strong
enough to abandon the recommendation,
while other panel members believed that the
recommendation for CBE was not evidence-
based and should be eliminated.
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Breast Self-Examination and Self-Detection
The goal of periodic BSE, as with CBE, is to
detect palpable tumors. An additional role of
BSE is to increase awareness of normal breast
composition, so that there is heightened
awareness of changes that may be detected
during BSE or at some other time.The value of
heightened awareness, however it may be
achieved, is commonly acknowledged65-67 based
on the value of earlier treatment of both
nonpalpable and palpable breast cancers.
Stockton, et al. attributed a shift toward more
favorable stage at diagnosis and declining breast
cancer mortality in the 1980s in East Anglia to
increasing awareness and prompt reporting of
signs and symptoms of breast cancer that 
began before the beginning of a breast cancer
screening program.68
The first studies suggesting possible
effectiveness of BSE were published in 1978.69,70
These two studies and many additional studies
in the premammography era found that in
general, women who reported that they had
been BSE performers had their breast cancers
detected at a smaller size and at earlier clinical
and/or pathologic stage. Regular performance
of BSE did not mean that the breast cancer was
necessarily self-detected during a formal BSE
procedure. Even regular BSE performers
commonly detected their breast cancer
incidentally, suggesting that there was a
component of increased body awareness (or
perhaps increased awareness of subtle
symptoms) in addition to the self-performed
physical examination.71
The literature on the effectiveness of BSE as
a detection modality has shown mixed results,
but recent evidence reviews have focused on
the absence of direct evidence of benefit in two
RCTs,72,73 and data indicating that the rate of
benign biopsy is higher in women who
regularly perform BSE compared with women
who do not regularly perform BSE.73 The
USPSTF concluded that the evidence is
insufficient to recommend for or against
teaching or performing routine BSE.23 The
Canadian Task Force on Preventive Health
Care went further and recommended against
routine instruction in BSE in periodic health
examinations on the basis of fair evidence of no
benefit and good evidence of harm (false-
positive results).65 The Canadian Task Force did
recommend that women should be taught to
promptly report any breast changes or
concerns, and those women who choose to
practice BSE should receive careful instruction
as well as information about risks, benefits, and
limitations. However, in an accompanying
editorial, Nekhlyudov and Fletcher argued that
the existing data do not provide a sound basis
for dismissing the value of BSE based on both
the limitations in the RCT data and
observational studies, and on the basis of the
principle that when evidence is lacking, it is
best to err on the side of prudence.74
There are a number of methodological
challenges to the evaluation of BSE, not the
least of which is the difficulty of measuring
adherence and competence. While early and
recent null results from the Shanghai trial73,75 are
commonly cited as evidence that BSE is
ineffective,66,67 the investigators have cautioned
that the trial was a study of BSE instruction and
not BSE per se, and that it should not be
inferred that there would be no reduction in
the risk of dying from breast cancer if women
practiced BSE competently and frequently.
However, the findings do suggest that in
populations where heightened awareness and
prompt reporting of breast symptoms is
common, BSE may offer less potential for
earlier interventions than in populations where
awareness is low and presentation of large,
advanced tumors is more common. The value
of BSE may be even lower for women with
heightened awareness who are having regular
mammograms.
As with CBE, it is unclear what BSE
instruction, irregular BSE, or adherent, highly
competent BSE contributes to earlier detection
of and reduced mortality from breast cancer.
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However, given variable adherence to screening
guidelines, imperfect sensitivity, and uneven
access to mammography, incidental self-
detection of breast cancer still accounts for a
significant percentage of incident cases. For
these and other reasons, women should be
encouraged to be aware of how their breasts
look and feel in order to be able to recognize
any changes and promptly report them.
As with CBE, there were some panel
members who believed that the evidence
against a benefit of BSE is not strong enough 
to abandon the recommendation, while other
panel members believed that there was
insufficient evidence to continue to recom-
mend BSE.
Need for Further Research 
The evidence supporting the value of CBE
and BSE is largely inferential.The most recent
literature reviews revealed the limitations of the
current data for drawing evidence-based
conclusions about the value of physical exams.
The ACS review panel recognized that there
were fundamental questions about the value 
of physical examinations in average-risk
asymptomatic women that should be addressed
in a research agenda.The actual contributions of
CBE and BSE to the detection of breast cancer,
training and performance issues, the importance
of heightened awareness of breast cancer signs
and symptoms, as well as understanding how
that awareness is achieved and maintained,
represent important areas for research.
MAMMOGRAPHY SCREENING IN OLDER WOMEN
Recommendation
Screening decisions in older women should
be individualized by considering the potential
benefits and risks of mammography in the
context of current health status and estimated life
expectancy.As long as a woman is in reasonably
good health and would be a candidate for
treatment, she should continue to be screened
with mammography. However, if an individual
has an estimated life expectancy of less than three
to five years, severe functional limitations, and/or
multiple or severe comorbidities likely to limit
life expectancy, it may be appropriate to consider
cessation of screening. Chronological age alone
should not be the reason for the cessation of
regular screening.
Rationale and Evidence
The size of the older population is growing
exponentially. Persons over age 65 years
currently represent approximately one-eighth of
the US population (35 million), and their
numbers are expected to double in the next 20
years (accounting for one in five Americans).76
Increasing numbers of women and their health
care providers are faced with questions about
whether and when to end breast cancer
screening. They will be required to make
judgments on the balance between the potential
benefits of screening—reduction of breast
cancer morbidity and mortality resulting from
early detection—and potential harms, which
among women with comorbidity or limited
longevity could cause suffering and diminished
quality of life in remaining years without
appreciable benefit.The balance of this equation
shifts with chronological age, life expectancy,
comorbidity, and functional limitation.
Disease Burden
Diagnosis of invasive breast cancer in women
aged 65 and older accounts for approximately
45 percent of all new breast cancer cases,77 and
diagnosis of breast cancer in women aged 65
and older accounts for about 45 percent of all
breast cancer deaths.78 Breast cancer mortality
increases with advancing age, ranging from 86
deaths per 100,000 women aged 65 to 69 years
to 200 deaths per 100,000 women aged 85
years and older.79 Although incidence and
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mortality rates are higher in older women, the
question of screening in this population must
be considered in the context of competing risks
of death from comorbid conditions, limited
longevity, and a woman’s overall health status.
Characteristics of the Disease: Biology of Breast
Cancer in Older Women
Theoretical considerations suggest that older
women may have a higher prevalence of less
aggressive tumors than younger women.80 In
general, the growth rate of a tumor is related to
its aggressiveness: if less aggressive tumors 
have longer sojourn times (i.e., a longer
mammographically detectable preclinical
phase), they are also more likely to become
manifest later in life and to be more prevalent
among older individuals. Clinical observations
support this hypothesis. Nixon, et al.81 and
Lyman,et al.82 have shown that the prevalence of
poorly differentiated (Grade 3) tumors
decreases, and the prevalence of hormone
receptor-rich tumors increases as the age of the
patient population increases. Evidence also
suggests that growth and metastatic spread of
breast cancer is slower in older women
compared with younger women. In a series of
819 Finnish women, Holmberg, et al.83 found
that for tumors of similar size, the prevalence of
axillary lymph node involvement decreased
with the age of the patient after age 55. Tabár
and colleagues reported that for any given
tumor size, the presence of Grade 3 tumors and
the likelihood of nodal involvement are lower in
older women compared with younger women.19
These data indicate that the prevalence of less
aggressive tumors increases with age.
While overall lower aggressiveness of breast
cancers in older women offers greater potential
for detection at a favorable stage and successful
treatment, it is important to emphasize that
breast cancer is a potentially lethal disease at any
age. Regardless of patient age, larger tumor size
is associated with higher nuclear grade, greater
risk of nodal involvement, and a poorer
outcome. Thus, the greater prevalence of less
aggressive tumors should not result in less
vigilant efforts focused on early detection and
treatment of breast cancers in older women.
Effectiveness of Mammography in Older Women
There are limited data on the efficacy of
screening mammography in women over the
age of 69. Only one RCT included women
older than 69.21 Published screening studies
have concluded that the performance and
effectiveness of mammography is at least as
good if not better in women aged 70 and older
compared with younger women.84,85 In the
absence of more definitive data, groups that
have issued screening guidelines have reached
the same conclusion.23
Rosenberg, et al. used a population-based
database and statewide tumor registry in New
Mexico to study the factors (including age)
affecting mammography sensitivity and stage at
diagnosis.86 Among women 65 and over
(47,000 examinations), sensitivity was 81
percent; the sensitivity for women aged 50 to
64, 40 to 49, and less than 40 was 78 percent,
77 percent, and 54 percent, respectively. For
women older than 65 who did not have dense
breasts, Rosenberg’s study showed that the
sensitivity for the detection of breast cancer was
comparable regardless of whether the women
used hormone replacement therapy (83 percent
versus 86 percent). However, for women over
age 65 with dense breasts, screening
mammography sensitivity was lower among
women on hormone replacement therapy
compared with women not on hormone
replacement (64 percent versus 84 percent).86
Because there are many complex issues,
unanswered questions, and research needs
related to hormone replacement therapy and
mammographic density, there is insufficient
evidence at this time to make a specific
recommendation regarding differential screen-
ing for older women who take hormone
replacement therapy and/or who have radio-
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graphically dense breasts.
Faulk87 compared data for women in the age
groups 50 to 64 and 65 and over. Abnormal
mammogram interpretations and number of
biopsies were comparable among the women in
both groups, but positive predictive value,
biopsy yield, and rate of cancers per thousand
screens were higher in the older age group as
would be expected on the basis of higher
disease prevalence. In the same study, there also
was a tendency toward lower stage at diagnosis
in the group of older women.
Data from the screening mammography
program of British Columbia88 showed
comparable abnormal interpretation rates for
women aged 70 and above compared with
women 40 to 69 but higher cancer detection
rates. Medical audit data from the University of
California, San Francisco,89,90 on a small number
of older women showed similar results. In other
words, while the likelihood of an abnormal
mammogram is similar across age groups, the
cancer yield is greater with increasing age.
Smith-Bindman, et al.91 studied female
California Medicare beneficiaries aged 66 to 79
years. In this series, the risk of detecting
metastatic breast cancer was significantly
reduced among women 60 to 79 years who
underwent screening mammography, with a
RR of 0.57 (CI 0.45 to 0.72). Although these
data are indirect, these findings are consistent
with evidence from the randomized trials
demonstrating that sensitivity increases due to
decreased density, and positive predictive value
increases due to high prevalence, making yield
higher in older versus younger women.
Sojourn Time and Screening Interval
As noted earlier, the length of the sojourn
time increases with increasing age, and is
estimated to be approximately four years for
women aged 70 to 79.19 Longer sojourn times
in older women have raised the question of
whether a subset of screen-detected incidence
cases represent overdiagnosis, i.e., detection of
cases that would not have been manifested
clinically in the patient’s lifetime. One method
of estimating overdiagnosis is the prevalence
screen predictive index (PSPI), which is the
proportion of tumors diagnosed at a prevalence
screen that would have arisen clinically if
screening had not taken place. From evaluation
of Two-County Trial data,Tabár and colleagues
estimated that the percentage of the PSPI
tumors for women aged 70 to 79 is 87 percent,
and for women aged 50 to 69 it is 100
percent.19 Thus, there is little or no evidence to
suggest that there is significant overdiagnosis of
breast cancers by mammographic screening of
older women.
As noted above, Field, et al. showed that
shorter screening intervals in women aged 65
and over also were associated with more
favorable tumor characteristics.43 In this small
study, the average tumor size in women who
had undergone annual screening (N = 93) was
10.7 mm (median = 9.5 mm), and for women
who had undergone biennial screening (N =
27), the average tumor size was 16.5 mm
(median = 15 mm). Seventy-two percent of the
women who had undergone annual screening
had a tumor T1bN0 or less, whereas only 44
percent of the women who underwent biennial
screening were of comparable stage.
The lengthening of the sojourn time with
increasing age was among the important factors
contributing to greater mortality reductions
observed in older versus younger women in the
RCTs92 and is a basis for offering screening at
wider intervals to older women in some service
screening programs. However, inferential
evidence suggests that annual screening still
results in more favorable tumor characteristics
at diagnosis compared with screening every two
years, although the magnitude and importance
of this difference is less for postmenopausal
women compared with premenopausal
women. Based on inferential evidence and
expert opinion, the majority of panel members
endorsed continuing to recommend annual
screening for younger and older women.
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Comorbidity and Breast Cancer
With advancing age, incidence of breast
cancer remains high, breast cancer mortality rate
increases, but overall life expectancy decreases.
Because the survival benefit from screening
mammography takes several years to emerge,
consideration of the effectiveness of screening
mammography in older women must address
issues of comorbidity and life expectancy as well
as questions of test performance.93,94
In the National Health Interview Survey
(NHIS), the percentage of women who
reported two or more comorbid conditions
increased from 45 percent among those aged 60
to 69 years to 61 percent for those aged 70 to
79 to 70 percent for those aged 80 years and
over.95 Results of one national study indicated
that many older people with cancer are
concurrently being treated for other conditions
that include arthritis, hypertension, and heart
disease.96 However, these data also revealed that
there are significant numbers of older
individuals who are in good health. A central
issue is whether detecting early stage breast
cancer confers an advantage among women
with comorbidity as it does among women
without comorbidity. Breast cancer patients
with comorbidity have poorer chances of
survival than patients without comorbidity after
adjustment for other prognostic indicators, such
as stage of disease at diagnosis, tumor grade, and
histology.97-102 Diabetes, renal failure, stroke, liver
disease, and a previous cancer were among the
conditions that predicted early mortality among
women with breast cancer.97,102 Satariano and
Ragland found that the relative risk of breast
cancer death declined, but the relative risk of
deaths due to other causes increased as the
number of comorbid conditions increased.97 A
study by McPherson and colleagues based on
breast cancer cases detected by screening
mammography in women aged 65 to 101 from
the Upper Midwest Oncology Registry System
found a significantly lower relative risk of death
for women without multiple comorbidities
than for women with multiple comorbidities.
However, women with multiple or severe
comorbidities comprised only 13 percent of
5,186 women.85 It is important to remember
that many women in older age groups will not
have comorbidity severe enough to negate the
benefits in survival and quality of life derived
from screening.
Life Expectancy
At age 70, the average life expectancy for a
woman in the United States is 15.4 years.
Indeed, even women at very advanced ages may
be expected to have considerable additional
years of life, as is shown in Table 3.
Cancer screening decisions in older women
are complicated by the heterogeneity in health
status of this population. As noted above, there
is great variation in number and severity of
comorbidities, suggesting that screening
guidelines based solely on chronological age are
incomplete. Figure 1 shows the distribution of
life expectancy for US women according to the
upper, middle, and lower quartiles of life
expectancy at each age. For example,
approximately 25 percent of 75-year-old
women will live more than 17 years, 50 percent
will live at least 11.9 years, and 25 percent will
live less than 6.8 years.93
In using Figure 1 to anchor life expectancy
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Average Life Expectancy for Women Aged 65
and Over*  
Age Average Life Expectancy  
65 19.1  
70 15.4  
75 12.1  
80 9.1  
85 6.6  
90 4.8  
95 3.5
TABLE 3
*Life Table for Females: United States, 1999, National Vital
Statistics Report, Vol. 50, No. 6, March 21, 2002.
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estimates, physicians can assess many clinical
variables to determine whether a woman is
typical of someone in the lower quartile of life
expectancy for her age or is more likely to be
in the middle or upper quartile.103 For example,
conditions such as congestive heart failure
(Class III or IV), end-stage renal disease on
dialysis, oxygen-dependent chronic obstructive
pulmonary disease, or moderate to severe
dementia104,105 would result in a life expectancy
in the lowest 25th percentile. Figure 1 shows
that women 80 years old and older in the
lowest quartile have life expectancies of less
than five years, so the likelihood that they will
benefit from screening mammography is
comparatively lower than women in upper
quartiles.96 Conversely, up until age 85, most
women have a life expectancy exceeding five
years, as do some very healthy 90-year-old
women.These women potentially may benefit
from screening mammography. These data
reveal that estimating longevity requires con-
sideration not only of chronological age but
also the presence of chronic conditions.
Finally, some older women with physical 
or cognitive problems may be particularly
vulnerable to the burdens, discomfort, and
anxiety associated with screening.93 However,
there is evidence that some physicians
overestimate physical, cognitive, and even
financial burdens of screening,106,107 and may fail
to refer older women for mammography based
Volume 53 • Number 3 • May/June 2003 157
CA Cancer J Clin 2003;53:141-169
0
5
10
15
20
25
70 75 80 85 90 95
15.7
21.3
9.5
17 
11.9 
6.8
13 
8.6
4.6
9.6 
5.9 
2.9
6.8 
3.9 
1.8
4.8 
2.7 
1.1
Top 25th Percentile
50th Percentile
Lowest 25th Percentile
Li
fe
 E
xp
ec
ta
nc
y 
fo
r 
W
o
m
en
 (y
ea
rs
)
Age (years)
*Data from the Life Tables of the United States 1997. Adapted from Walter LC, Covinsky KE. Cancer screening in elderly patients: A framework for
individualized decision making. JAMA 2001;285:2750-2756.
FIGURE 1
Upper, Middle, and Lower Quartiles of Life Expectancy for Women at Selected Ages* 
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on the anticipation that the patient will refuse
to be screened. These are challenging
circumstances for the physician and the patient,
and there will be individuals where foregoing
screening is appropriate.Talking to patients and
if appropriate, with an involved caregiver, about
personal preferences and the balance of benefit
to harm can lead to a shared decision that is
appropriate.93
Though estimations of life expectancy that
incorporate severity of comorbidity and
functional impairments are imperfect predictors
of longevity, they allow for a more complete
consideration of the potential benefits and
harms of screening mammography than simply
focusing on chronological age.
ACCEPTABILITY, QUALITY OF LIFE, AND HARMS
ASSOCIATED WITH SCREENING
Although the majority of women
understand that false-positive test results are 
an inevitable part of screening,48 abnormal
mammogram results can result in significant
short-term psychological distress as well as
increased health care utilization and costs.49,108,109
Previous work has identified a number of
domains, particularly psychosocial, that are
affected during the interval from notification of
an abnormal mammogram to determination
that cancer is absent.Though the overwhelming
majority of these studies have been conducted
in younger women, there is no reason to believe
that the effects of a false-positive screening
result will vary substantially by age. However,
these effects, when noted, are generally
transient,47,110-112 have no effect on endocrine
and immunological function,113 and are
inversely related to the time from abnormal
notification to resolution with a result of
benign pathology.47 The short-term experiences
following false-positive mammogram results
have not been consistently linked to future
screening behaviors.114
One concern frequently raised about
screening older women with a life expectancy of
five to ten years is the detection and treatment,
including overtreatment, of DCIS. As stated
earlier, detection of DCIS is an inevitable
consequence of mammography screening. The
rate of screen-detected DCIS increases with age
but is a lower proportion of screen-detected
breast cancers in older women compared with
younger women.115 It is important to note that
the incidence rate of invasive disease dwarfs that
of DCIS, and it is not currently possible to
identify which in situ cancers will progress to
become invasive.While it would be shortsighted
to forgo screening older women because of the
possibility of detecting DCIS, treatment decisions
for older women with DCIS should include
consideration of life expectancy and health status.
EARLY DETECTION OF BREAST CANCER IN
WOMEN AT INCREASED RISK 
Recommendation 
Women at increased risk of breast cancer
might benefit from additional screening
strategies beyond those offered to women of
average risk, such as earlier initiation of
screening, shorter screening intervals, or the
addition of screening modalities (such as
ultrasound or magnetic resonance imaging
[MRI]) other than mammography and physical
examination. However, the evidence cur-
rently available is insufficient to justify
recommendations for any of these screening
approaches. In lieu of recommendations, points
of discussion have been developed for women
at increased risk and their health care providers
when considering screening options. These
points are based on the limited available
evidence and expert opinion. Decisions about
screening options for women at increased risk
of breast cancer should be based on shared
decision-making after a review of potential
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benefits, limitations, and harms of different
screening strategies and the degree of
uncertainty about each. In order to pursue
answers to unresolved questions, important
elements of a research agenda are identified, and
efforts to collect needed outcome data are
encouraged.
Identification of Women at Significantly 
Increased Risk
Over the years, a number of risk factors have
been identified for breast cancer.116-125 Overall,
the most important risk factors are age and sex.
Although approximately one percent of all cases
are in males, the remainder is in females, and
risk increases with age.After controlling for age,
the greatest increase in risk has generally been
associated with a family history of breast and/or
ovarian cancer, with the number, type, and age
at onset of affected relatives being important
determinants of risk.124,125 Within the group of
women with a family history of breast and/or
ovarian cancer, a relatively small subset of
women with inherited mutations deserves
special mention. Over the past decade, two
breast/ovarian cancer susceptibility genes have
been identified, named BRCA1 and
BRCA2.126,127 Women who are known carriers
of mutations in either of these two genes have
particularly high risks of breast and ovarian
cancer. Although only laboratory testing can
confirm that a woman carries a deleterious
mutation in one of these genes, genetic and
epidemiologic studies document several family
history characteristics that suggest an increased
risk of breast cancer.These reflect the autosomal
dominant mode of inheritance128-130 and
include:
• Two or more relatives with breast or ovarian
cancer;
• Breast cancer occurring before age 50 in an
affected relative;
• Relatives with both breast and ovarian
cancer;
• One or more relatives with two cancers
(breast and ovarian cancer or two independent
breast cancers);
• Male relatives with breast cancer;
• A family history of breast or ovarian cancer
and Ashkenazi Jewish heritage.
In general, the likelihood of inherited breast
cancer risk is higher when the biologic
relationship of the affected relative is closer, e.g.,
when cancer occurs in a first-degree relative
(such as a mother or sister) rather than in a
second-degree relative (such as a grandmother
or aunt). However, risk can be inherited equally
from maternal and paternal sides of the family,
and when risk is inherited from the paternal
side, there may be no apparent affected first-
degree relatives.
Several statistical models exist that attempt to
predict the risk of breast cancer for women with
identifiable factors associated with the
disease.125,129,131-134 A quantitative evaluation of
family history to determine the likelihood of
BRCA1/2 mutations and to estimate lifetime
risk of breast cancer can be accomplished with
the BRCAPRO statistical model.129,133The Claus
statistical model can be used to estimate either
short-term or lifetime risk of breast cancer
based on family history and age of cancer onset,
and is particularly useful for women with
affected first- and second-degree relatives.125,134
The Gail model131 can also be used to estimate
short-term and lifetime risk of breast cancer.
This model estimates five-year and lifetime risk
of breast cancer based on age of menarche, age
at birth of first child, number of breast biopsies,
the presence of atypical hyperplasia discovered
by breast biopsies, and family history (scored as
zero, one, or two first-degree relatives with
breast cancer). Because the Gail model uses
limited family history information, it should not
be used if the patient’s family history is the
primary source of risk.135
Each of these models has strengths and
weaknesses, and an individual woman’s risk
estimates may vary with different models.136 In
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addition, it has been shown that while these
models are accurate for groups of women with
a particular risk factor, they are less successful in
estimating risk for an individual woman.137,138
Thus, the risk estimates generated from these
models should not be considered precise but
rather a means to identify subsets of women at
increased risk.
The threshold for defining a woman as
having elevated risk of breast cancer is based on
expert opinion.Any woman with a BRCA1 or
BRCA2 mutation should be considered at high
risk. If mutation testing is not available, or has
been done and is noninformative, pedigree
characteristics suggesting high risk (as noted
above) are also considered to be an indicator of
increased risk. Risk assessment is likely to offer
the greatest potential benefit for women aged
less than 40.
Additional factors that increase the risk of
breast cancer and thus may warrant earlier or
more frequent screening include previous
treatment with chest irradiation (e.g., for
Hodgkin disease), a personal history of breast
cancer, or a family history of diseases known to
be associated with hereditary breast cancer such
as Li-Fraumeni or Cowdens Syndromes.
Screening Options for Women at Increased Risk 
Four screening options may be considered
for women at increased risk of breast cancer:
• Initiation of mammography screening at age
30 or, rarely, at younger ages;
• Shorter mammography screening intervals,
e.g., every six months;
• Addition of MRI screening;
• Addition of ultrasound screening.
Initiation of Mammography Screening 
at Age 30 
The age at which screening should be
initiated for women at high risk is not well
established.The argument for early screening is
based on the cumulative risk of breast cancer in
women with BRCA1 mutations and a strong
family history of early breast cancer, which is
estimated to be three percent by age 30 and 19
percent by age 40.139 Population-based data also
indicate that risk for early breast cancer is
increased by a family history of early breast
cancer.134,140 Based on these observations, some
experts have suggested that breast cancer
screening begin five to ten years prior to the
earliest previous breast cancer in the family. In
1997, an expert panel suggested that screening
be initiated at some time between the ages of
25 and 35 for women with a BRCA1 or
BRCA2 mutation.141 Because these recom-
mendations were based on limited obser-
vational data, the decision regarding when to
initiate screening should be based on shared
decision-making, taking into consideration
individual circumstances and preferences.
Mammography
There are no RCT data and few obser-
vational data to assess mammography screening
in high-risk women younger than age 40.
Although a number of observational studies have
evaluated screening in young women at
increased risk, most of the subjects in these
studies have been between the ages of 40 and 50.
However, the breast cancer incidence observed
in these studies confirms that family history
indicators and BRCA1/2 mutation status can
identify women at increased risk of breast cancer,
and that mammography has performance
characteristics in high-risk young women similar
to those in women from the general population
at older ages.90,142 High-risk women under age 50
who have regular screening are more likely to be
diagnosed at earlier stages and tend to have more
favorable tumor characteristics than those who
do not have regular screening.Thus, initiation of
mammography screening under age 40 may
permit the identification of early breast cancer in
women at significantly elevated risk, in
160 CA A Cancer Journal for Clinicians 
ACS Guidelines for Breast Cancer Screening: Update 2003
 by guest on July 31, 2007 (©American Cancer Society, Inc.) 
ca
o
nline.am
cancersoc.org
D
ow
nloaded from
 
particular, women with BRCA1 and BRCA2
mutations.143
Sensitivity and specificity of mammography
are not well established in women under age
40. In general, accuracy measured by both
sensitivity and specificity is lower in younger
women compared with older women but still is
favorable, and both sensitivity and specificity
improve incrementally as women get older.90
Several studies have provided evidence for an
increased risk of breast cancer after therapeutic
radiation exposure or multiple exposures to
diagnostic radiation.144-146 Overall risk from
single and cumulative diagnostic exposures is
small, but risk increases with the amount of
exposure and with younger age at
exposure.146,147 Thus, it is theoretically possible
that cumulative radiation exposure associated
with screening mammography increases the
risk of breast cancer.148 It has also been
hypothesized that some women at increased
inherited risk for breast cancer may also have
increased radiation sensitivity, which could
increase their risk for radiation-induced breast
cancer. This hypothesis may be plausible
because studies of BRCA1 and BRCA2 suggest
that these genes code for functions related to
repair of radiation damage to DNA.149-153
However, in a report from a multi-institutional
study, there was no evidence of increased
radiation sensitivity in 71 BRCA1/2 carriers
receiving radiotherapy after breast-conserving
surgery, within the five-year follow-up of the
study.154,155 In addition, in a second study, family
history did not influence treatment outcome
among women who received breast-conserving
surgery and radiation therapy.156 Even if the
highest estimates of increased risk of radiation-
induced cancers from low mammographic
doses beginning at a younger age are true, the
risk-benefit equation still favors mammography
screening for most or all women, particularly if
radiation exposure from the screening process is
kept as low as possible.148 However, given
concerns and uncertainties about possible
radiation risk, it is important not to screen
young women for whom there is not a firm
basis for assigning high risk, and to limit
radiation exposure during the screening process
to the lowest level that still ensures a favorable
image. Further, as part of a decision-making
process, women should be informed about the
uncertain but still unlikely potential for
radiation-induced cancers as a possible harm
associated with regular screening at young ages
(e.g., age 30 or, rarely, younger).
Clinician Examination and Breast 
Self-Examination
There are limited data on the effectiveness of
CBE and BSE in high-risk women. A recent
study from Memorial Sloan-Kettering Cancer
Center suggested a value for BSE in that five
breast cancers were detected by BSE less than a
year after a previous screen among a cohort of
high-risk women (as compared with one
cancer detected by clinical exam and 11 cancers
detected as a result of mammographic
screening). However, it was not clear in this
study whether the detection of interval cancers
occurred through deliberate self-examination
according to instruction or whether discovery
occurred during the course of normal
activities.157,158 There are no systematic studies in
high-risk women that evaluate harms
(including anxiety, false-positive work-ups, and
complacency) associated with physical exam,
and there has been no systematic comparison of
different screening intervals.
Mammography Screening Intervals of Less 
Than One Year
There are no known studies that evaluate a
semi-annual versus annual screening interval,
although those comparing annual versus
biennial favor annual screening. Recom-
mendations for shorter intervals have generally
been based on the incidence of interval cancers
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and modeling data.40,157 An important potential
research question relates to what extent the
incidence of interval cancer diagnoses should
be used as a basis for recommending more
frequent screening. It is not clear whether
interval cancers in younger women at increased
risk are attributable to faster tumor growth 
rates and shorter sojourn times or to greater
difficulty in imaging dense parenchyma.40 Data
from the Two-County trial showed that women
with family histories of breast cancer had
tumors with faster growth rates than those
without family histories of breast cancer, but
the difference was not large.159
Alternative Screening Modalities for Women 
at Increased Risk
Several groups of investigators have evaluated
the relative contributions of mammography,
MRI, and ultrasound in women with either a
family history of breast cancer or a documented
BRCA1/2 mutation. In addition to the
published studies, there are several ongoing
MRI high-risk screening studies throughout the
world, including the United States, Canada,
England, Germany, the Netherlands, France, and
Italy. These studies suggest that MRI or
ultrasound may be beneficial if used as an
adjunct to mammography for women with an
increased risk of breast cancer, but not as stand-
alone tests. The following discussion pertains
only to women at increased risk; alternative
screening modalities for women at average risk
are covered in the next section on new
technologies.
Studies of screening MRI in younger high-
risk women have found that sensitivities and
cancer yields were improved over those of
mammography. Specificity of MRI varied
according to follow-up management but was
generally lower than that of screen-film
mammography.160-163 In studies in which both
prevalent (first) and incident (subsequent)
screens were performed, the higher yield of
cancers detected with MRI was true for both
prevalent and incident screens.
Even as studies report high sensitivity with
MRI, there are substantial concerns about costs
and limited access for women with familial risk.
In addition, MRI-guided biopsies are not
widely available. Since false-positive results
appear to be common,more data are needed on
factors associated with lower specificity rates.
Among higher risk women undergoing MRI,
there are no data on anxiety and quality of life
effects related to false-positive results.
There have not been any studies of
ultrasound as a screening modality in high-risk
women. (See discussion below regarding the
use of ultrasound in average-risk women.) 
Need for Further Research
In order to address unanswered clinical
research questions, whenever feasible, women at
increased risk should be enrolled in protocols
assessing early screening, more intensive
screening, and the use of new screening
modalities. Screening MRI should take place in
centers with extensive experience in diagnostic
MRI and that have the capacity to perform
MRI-guided biopsies. Many women at
increased risk are currently being screened with
MRI and ultrasound outside of clinical trials.
Collection of observational data and
development of a national MRI screening
registry should be strongly encouraged. While
some experts have expressed concerns about
these tests being used outside of clinical trials
before they are shown to be efficacious for
screening, others are concerned about limiting
these tests only to those women at increased
risk who have access to these trials.
CURRENT STATUS OF NEW TECHNOLOGIES FOR
BREAST CANCER SCREENING FOR WOMEN OF
AVERAGE RISK
Imaging Technologies
Screen-film mammography (SFM) is the
current gold standard for breast cancer
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screening.164 New technologies proposed for
breast cancer screening must equal or,
preferably, exceed the performance of SFM in
order to find acceptance as screening tools.
New technologies for breast cancer screening
should aim at identifying more of the cancers
that are missed by SFM, identifying a higher
fraction of early stage cancers (Stages 0 and I),
and identifying which early stage cancers
require aggressive treatment or no treatment. In
addition, any new technology should meet the
goals of an ideal screening tool, i.e., it should be
simple to perform, noninvasive, cost-effective,
and widely available and acceptable to patients.
A list of potential new technologies for breast
cancer screening is included in Table 4. Several
of these modalities have been Food and Drug
Administration (FDA) approved for clinical use,
but in most cases, not explicitly for breast cancer
screening. One recently approved technology
that also has been approved for breast screening
and diagnostic use is full-field digital
mammography (FFDM). To obtain FDA
approval, FFDM manufacturers had to
demonstrate that their digital mammography
systems were not inferior to screen-film
mammography in terms of sensitivity, specificity,
and receiver-operator characteristic (ROC)
curve areas. Three FFDM manufacturers have
received FDA approval. As of September 2002,
there were approximately 300 FFDM systems in
clinical use in the United States.
The only completed study comparing
FFDM to SFM in a screening cohort was done
on a single manufacturer’s prototype system at
two sites.165,166 FFDM had a significantly lower
recall rate (11.8% versus 14.9%, P > 0.001) and
significantly lower biopsy rate than SFM (94
versus 143 out of 6,736 exams, P < 0.001).
However, FFDM had insignificantly lower
sensitivity.166
Computer-Aided Detection and Diagnosis
Over the last two decades, computer-aided
detection and diagnosis (CAD) has been
developed to aid radiologists in detecting
mammographic abnormalities suspicious for
breast cancer.167,168 Three commercial systems
designed to digitize screen-film mammograms
and analyze them for suspicious lesions have
received FDA approval for clinical use. There
are approximately 500 CAD systems installed in
the United States. Only one commercial CAD
system has been approved by the FDA for use
with digital mammography. Several clinical
studies have been conducted to evaluate the
effectiveness of commercial CAD systems in
aiding radiologists in the performance and
interpretation of screening mammography.169-171
In the largest clinical series to date,170
radiologists reading with CAD increased their
overall screening recall rate from 6.5 percent to
7.7 percent (an 18.5 percent increase), while
increasing the number of detected cancers from
41 percent to 49 percent (a 19.5 percent
increase) compared with interpretation without
CAD. Use of CAD increased overall detection
rate from 3.2 to 3.8 cancers per 1,000 women
screened. These results suggest that CAD
systems may aid the average radiologist by
substantially improving detection of early stage
malignancies with no more than a
proportionate increase in recall rate.
With the potential use of ultrasound and
breast MRI for screening (see below),
development of CAD systems is underway to
aid breast ultrasound and breast MRI
interpretations. Most CAD methods for these
two modalities have focused on
characterization of identified breast lesions.172,173
Recently, however, new methods have been
developed for the detection of lesions on
ultrasound.174
Ultrasound
Ultrasound has become a valuable diagnostic
adjunct to mammography because it is widely
available and relatively inexpensive to perform.
Usually, however, breast ultrasound is used
clinically as a targeted exam, limiting scanning
to the focal area of concern.175 Recent
improvements in breast ultrasound technology
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and its application have demonstrated that
ultrasound can help distinguish not only
between cyst and solid masses but also between
benign and malignant masses.176 Ultrasound
may also be used to perform image-guided
biopsy of a mass, which allows histologic
and/or cytologic assessment for abnormalities
detected through the screening process.
Prevalence screening studies in women with
radiographically dense breasts have reported
164 CA A Cancer Journal for Clinicians 
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Potential New Imaging Technologies for Breast Cancer Detection*
Current Level of Evidence FDA Approval FDA Approval
Supporting Use in for General Specifically for 
Technology Screening Clinical Use Screening
Screen-film mammography (SFM) A Yes Yes
Full-field digital mammography (FFDM)  B Yes Yes
Computer-aided detection with SFM B Yes Yes
Computer-aided detection with FFDM B Yes Yes
Ultrasound (US) B Yes No
Magnetic resonance imaging (MRI) B Yes No
Novel ultrasound methods 
(Doppler, 3D, compound scanning, etc.) C No No
Computer-aided detection with US C No No
Computer-aided detection with MRI C No No
X-ray computer tomography (CT) C Yes No
Scintimammography C Yes No
Positron emission tomography (PET) C Yes No
Elastography (MR and US) C No No
Magnetic resonance spectroscopy C No No
Optical imaging C No No
Optical spectroscopy C No No
Electrical potential measurements C No No
Electrical impedance imaging C Yes No
Electronic palpation C No No
Dedicated breast CT 
(x-ray, US, optical, thermoacoustic) C No No
Thermography D Yes No
Magnetomammography E No No
Microwave imaging E No No
Hall effect imaging E No No
TABLE 4
Key:
A = Strong clinical evidence for effectiveness in screening; technology is routinely used for screening.
B = Some clinical evidence for effectiveness or equivalence to screen-film mammography for screening. 
C = Preclinical data suggest possible promise, but clinical data are sparse or nonexistent; more study is needed.
D = Clinical evidence indicates that modality is ineffective as a screening tool.
E = Technology is not at the stage that data are available. 
*Adapted with additions and minor changes from Table 2-1, Institute of Medicine Report on New Technologies in
Breast Imaging, 2001. 
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three to four breast cancers per 1,000 women
that were detected by ultrasound only.175-180
Despite these findings, breast ultrasound has
known limitations as a screening tool. Breast
ultrasound requires a skilled operator, and the
numbers of radiologists and technologists
trained to perform the exam is limited. Other
concerns include the lack of standardized exam
techniques and interpretation criteria, the
inability of breast ultrasound to detect
microcalcifications, the variability of equip-
ment, and preliminary data suggesting a
substantially higher rate of false-positive exams
than mammography.175,178,179 Like mammo-
graphy, ultrasound has a lower specificity in
younger women.181
Studies of ultrasound imaging have shown 
an ability to find cancers not found on
mammography but with sensitivity inferior to
that of MRI.The value of ultrasound is greatest
for women with significant breast density.
Ultrasound is less sensitive than MRI, but has
the advantage of being more widely available
and considerably less expensive.
Magnetic Resonance Imaging
Over the past decade, MRI of the breast has
become a useful diagnostic adjunct to
mammography and breast ultrasound for
evaluation of breast cancer. When used with
intravenous injection of an FDA-approved MR
contrast agent, gadolinium DTPA, breast MRI
has been shown to be sensitive to 83 to 100
percent of breast cancers above a few
millimeters in size.182 A summary analysis of
breast MRI cases showed an overall sensitivity
to breast cancer of 96 percent.182 The high
sensitivity of breast MRI suggests that it might
also be useful in screening for breast cancer.
However, current concerns about the potential
of MRI as a screening test include costs, the
lack of standardized exam techniques and
interpretation criteria, the inability of MRI to
detect microcalcifications, the ultimate
sensitivity of the test, variability of equipment,
and preliminary data suggesting a higher rate of
false-positive exams than mammography.
Furthermore, as noted in the previous section,
MRI-guided biopsies are not widely available,
so it may not currently be feasible to follow up
findings detected by MRI that cannot be
visualized by other imaging technologies.
Other Imaging Technologies
Table 4 also includes potential new
technologies that are being investigated
primarily as diagnostic adjuncts to mam-
mography. Some, such as scintimammography,
positron emission tomography, and electrical
impedance imaging, have received FDA approval
as diagnostic adjuncts to mammography. None
of these new technologies has successfully
undergone clinical testing that would justify its
use in screening for breast cancer. Other
technologies on the list are still being
investigated in the laboratory setting and are not
yet ready to begin clinical evaluation.
Nonimaging Tests: Ductal Lavage
Ductal lavage is a procedure targeted to
asymptomatic women who are assessed to be at
significantly increased risk for breast cancer.183 It
was developed in order to collect breast duct
epithelial cells for cytologic analysis. There are
currently insufficient data to recommend the
use of ductal lavage either as an independent
screening modality or in combination with
screening mammography.
CONCLUSION
The guideline panel reaffirmed the value of
breast cancer screening based on updated results
from RCTs and new evidence published since
the last ACS guideline review in 1997.
However, each of the screening methods that
was considered has limitations, and there are
potential harms associated with false-positive
findings. Thus, women should be informed
both about the benefits and limitations of
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